阿立哌唑与利培酮治疗精神分裂症对照研究

A controlled study of efficacy between aripiprazole and risperidone in the treatment of patients with schizophrenia

目的:比较阿立哌唑与利培酮对精神分裂症的疗效及安全性。方法:选取70例精神分裂症患者,随机分为阿立哌唑组36例,利培酮组34例,分别给予阿立哌唑和利培酮治疗,疗程8周。在治疗前及治疗1、2、4、6、8周末分别采用阳性与阴性症状量表(PANSS)、治疗中出现的症状量表(TESS)对两组进行评定。并于治疗前、中、后检查催乳素水平。结果:两组治疗后PANSS评分均有显著下降。阿立哌唑组的锥体外系不良反应、体质量增加及月经失调均较利培酮组少而轻,对催乳素水平没有影响。结论:2药对精神分裂症均有较好的疗效,起效快,不良反应小。

Objective： To compare the efficacy and safety of aripiprazole and risperidone in the treatment of patients with schizophrenia. Method： 70 patients with schizophrenia were randomly divided into aripiprazole group （n =36） and risperidone group （n = 34） for 8 treatment weeks. Positive and negative syndrome scale （PANSS） and treatment emergent symptoms scale （TESS） were evaluated before and after 1,2,4, 6, 8 treatment weeks for both groups. The plasma prolactin level was measured before,during and after treatment. Results：The total scores of PANSS reduced significantly after treatment in both groups. Patients in aripiprazole group had mild adverse affects in extrapyramidal symptom, weight gain and abnormal menstruation cycle, and had no changes in plasma prolactin level, when compared with that risperidone group. Conclusion：Aripiprazole was as effective as risperidone in the teatment of patients with schizophrenia. Both of them are characterized with quick effect and less severe adverse effects.